Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
Wataru Shimizu, Yoshiaki Kubota, Yu Hoshika, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 157

Showing 1-25 of 157 citing articles:

Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Milton Packer
Circulation (2022) Vol. 146, Iss. 18, pp. 1383-1405
Open Access | Times Cited: 242
Empagliflozin in acute myocardial infarction: the EMMY trial
Dirk von Lewinski, Ewald Kolesnik, Norbert J. Tripolt, et al.
European Heart Journal (2022) Vol. 43, Iss. 41, pp. 4421-4432
Open Access | Times Cited: 196
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
James P. Curtain, Kieran F. Docherty, Pardeep S. Jhund, et al.
European Heart Journal (2021) Vol. 42, Iss. 36, pp. 3727-3738
Open Access | Times Cited: 173
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry
Pasquale Paolisso, Luca Bergamaschi, Gaetano Santulli, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 143
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
Hang‐Long Li, Gregory Y.H. Lip, Qi Feng, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 133
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry
Pasquale Paolisso, Luca Bergamaschi, Felice Gragnano, et al.
Pharmacological Research (2022) Vol. 187, pp. 106597-106597
Open Access | Times Cited: 84
Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction
Jacob A. Udell, W. Schuyler Jones, Mark C. Petrie, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 20, pp. 2058-2068
Open Access | Times Cited: 78
Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?
Paschalis Karakasis, Nikolaos Fragakis, Κωνσταντίνος Κούσκουρας, et al.
Clinical Therapeutics (2024) Vol. 46, Iss. 11, pp. 841-850
Closed Access | Times Cited: 15
The effect of sodium-glucose co-transporter 2 inhibitors on clinical outcomes after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials
Ubaid Khan, Ahmed Mazen Amin, Amira Mohamed Taha, et al.
Future Cardiology (2025), pp. 1-14
Open Access | Times Cited: 1
Impact of sodium‒glucose cotransporter‐2 inhibitors in patients with recent versus previous myocardial infarction: a systematic review and meta-analysis
Pedro Gabriel Scardini, Eric Katsuyama, A Prata, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Left Ventricular Remodeling after Myocardial Infarction: From Physiopathology to Treatment
Sabina Andreea Leancă, Daniela Crișu, Antoniu Octavian Petriș, et al.
Life (2022) Vol. 12, Iss. 8, pp. 1111-1111
Open Access | Times Cited: 66
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
Arturo Cesaro, Felice Gragnano, Pasquale Paolisso, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 60
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
Takayoshi Kanie, Atsushi Mizuno, Yoshimitsu Takaoka, et al.
Cochrane library (2021) Vol. 2021, Iss. 10
Open Access | Times Cited: 58
SGLT2 Inhibitors and Their Antiarrhythmic Properties
Ewald Kolesnik, Douglas S. Scherr, Ursula Rohrer, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1678-1678
Open Access | Times Cited: 42
Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
Husam M. Salah, Subodh Verma, Carlos G. Santos‐Gallego, et al.
Journal of Cardiovascular Translational Research (2022) Vol. 15, Iss. 5, pp. 944-956
Closed Access | Times Cited: 39
Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management
S. Williams, Siddig Abdel Raheim, Muhammad Ilyas Khan, et al.
Clinical Therapeutics (2022) Vol. 44, Iss. 10, pp. 1394-1416
Open Access | Times Cited: 37
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Yafei Xie, Yujie Wei, Dan Li, et al.
Journal of Cardiovascular Pharmacology (2023) Vol. 81, Iss. 1, pp. 4-14
Closed Access | Times Cited: 32
SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback
Ashish Upadhyay
Kidney360 (2024) Vol. 5, Iss. 5, pp. 771-782
Open Access | Times Cited: 7
Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence
Paschalis Karakasis, Dimitrios Patoulias, George Kassimis, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 27, pp. 2109-2119
Closed Access | Times Cited: 7
Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study
Jonas Oldgren, Sanna Laurila, Axel Åkerblom, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 7, pp. 1505-1517
Closed Access | Times Cited: 52
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
Robert Pietschner, Julie Kolwelter, Agnes Bosch, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 40
Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials
Alicia Swee Yan Yip, Shariel Leong, Yao Hao Teo, et al.
Therapeutic Advances in Chronic Disease (2022) Vol. 13
Open Access | Times Cited: 35
Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy
Ren Jie Phang, Rebecca H. Ritchie, Derek J. Hausenloy, et al.
Cardiovascular Research (2022) Vol. 119, Iss. 3, pp. 668-690
Open Access | Times Cited: 30
Effects of dapagliflozin on cardiac function and short-term prognosis of patients with both acute myocardial infarction and type 2 diabetes mellitus
Le ZHOU, Xiaohong GENG, Qian Hu, et al.
Minerva Cardiology and Angiology (2024) Vol. 72, Iss. 3
Closed Access | Times Cited: 6
Cardiovascular outcomes of sodium-glucose Co-transporter 2 inhibitors use after myocardial infarction: A systematic review and meta-analysis of randomized controlled trials
Abiodun Idowu, Olayinka Adebolu, Phuuwadith Wattanachayakul, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 8, pp. 102648-102648
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top